Clinical Trials Directory

Trials / Terminated

TerminatedNCT01795365

Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Centre Hospitalier Universitaire Vaudois · Academic / Other
Sex
Male
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Active Surveillance manages selected men with prostate cancer expectantly with curative intent. This means men are carefully selected and subsequently actively observed in order to have the possibility to offer them curative treatment once the tumor seems to progress. The goal of this study is to validate the treatment option Active Surveillance in men with localized, well differentiated prostate cancer, in order to limit the amount of overtreatment. A number of key points will be studied, such as the pathological findings in radical prostatectomy specimens, and the effect of expectancy on the quality of life.

Detailed description

Objectives: Primary \- To evaluate the equivalence of the time on active surveillance before an active treatment between group Epstein + and the expanded active surveillance group (Epstein -) Secondary * To evaluate the role of diffusion-weighted MRI (DW-MRI) in the initial diagnosis and the follow-up of patients under active surveillance * To evaluate the role of BCAR-1 to predict the clinical outcome of localized prostate cancer * To evaluate the proportion of patients who discontinued active surveillance * To evaluate the mortality at 10, 15 and 20 years from the inclusion in the study * To evaluate the time to radical treatment * To evaluate the time to metastatic disease * To evaluate patients quality of life

Conditions

Interventions

TypeNameDescription
OTHERActive surveillance

Timeline

Start date
2012-12-01
Primary completion
2018-07-01
Completion
2018-07-26
First posted
2013-02-20
Last updated
2018-09-28

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01795365. Inclusion in this directory is not an endorsement.